Number (%) of patients in the ATTAIN trial in RAPID3 response categories as compared to EULAR-DAS28 response categories.
| ATTAIN Trial Treatment Groups | EULAR-DAS28 Response Categories | EULAR-DAS28 No. (%) Patients | RAPID3 Response Categories, No. (%) Patients | ||
|---|---|---|---|---|---|
| Good (improve > 3.6 units) | Moderate (> 1.8 and ≤ 3.6 units) | Poor (improve ≤ 1.8 units) | |||
| Abatacept (kappa 0.37, weighted kappa 0.44) | Good | 30 (17) | 20 (67) | 6 (20) | 4 (13) |
| Moderate | 100 (56) | 23 (23) | 57 (57) | 20 (20) | |
| Poor | 50 (28) | 0 | 18 (36) | 32 (64) | |
| Total | 180 (100) | 43 (24) | 81 (45) | 56 (31) | |
| Control (kappa 0.48, weighted kappa 0.52) | Good | 4 (4) | 2 (50) | 2 (50) | 0 |
| Moderate | 29 (30) | 3 (10) | 18 (62) | 8 (28) | |
| Poor | 65 (66) | 1 (2) | 11 (17) | 53 (82) | |
| Total | 98 (100) | 6 (6) | 31 (32) | 61 (62) | |
| All patients (kappa 0.44, weighted kappa 0.51) | Good | 34 (12) | 22 (65) | 8 (24) | 4 (12) |
| Moderate | 129 (46) | 26 (20) | 75 (58) | 28 (22) | |
| Poor | 115 (41) | 1 (1) | 29 (25) | 85 (74) | |
| Total | 278 (100) | 49 (18) | 112 (40) | 117 (42) | |
ATTAIN: Abatacept Trial in Treatment of Anti-TNF INadequate Responders; EULAR: European League Against Rheumatism; DAS28: 28-joint Disease Activity Score; RAPID3: Routine Assessment of Patient Index Data.